The FDA on November 8, 2024, approved AUCATZYL®, a CD19-directed genetically modified autologous T cell immunotherapy, for adults with Relapsed or Refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL). AUCATZYL® is a product of Autolus Inc.
Bottom Ad
Advertisement
Subscribe
